Blood Inflammatory Mediators and Cognitive Decline in Alzheimer's Disease: A Two Years Longitudinal Study

J Alzheimers Dis. 2018;63(1):87-92. doi: 10.3233/JAD-171131.

Abstract

Peripheral inflammatory processes are involved in Alzheimer's disease (AD). We aimed to determine whether plasma inflammatory mediator levels at diagnosis are associated with cognitive decline through a 2-year follow-up in AD patients. Patients (n = 109, mean age 79.44 (6.82) years) were included at diagnosis with MMSE scores between 16 and 25, with C-reactive protein <10 mg/L, and without any acute or chronic inflammation status. Plasma IL-1β, IL-6, TNF-α, and CCL5 were measured using Luminex X-MAP technology at baseline, and after one year and two years of follow-up. The mean values of IL-1β, IL-6, TNF-α, and CCL5 at diagnosis were 0.3, 1.94, 6.57, and 69,615.81 pg/mL, respectively. Mean cognitive decline in MMSE was 3.35 points. No correlation between plasmatic value of IL-1β, IL-6, TNF-α, or CCL5 at diagnosis and cognitive decline during the two years of follow-up was found. Cognitive decline in AD does not appear to be predictable by the tested inflammatory mediators.

Keywords: Alzheimer’s disease; cognitive decline; cytokines; inflammation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / blood
  • Alzheimer Disease / complications*
  • C-Reactive Protein / metabolism
  • Cognition Disorders / blood*
  • Cognition Disorders / etiology*
  • Correlation of Data
  • Disease Progression
  • Female
  • Humans
  • Inflammation Mediators / blood*
  • Longitudinal Studies
  • Male
  • Mental Status Schedule
  • Neuropsychological Tests

Substances

  • Inflammation Mediators
  • C-Reactive Protein